Several other research analysts have also recently issued reports on the stock. Robert W. Baird increased their price target on shares of Eiger BioPharmaceuticals from $3.00 to $5.00 and gave the stock an “outperform” rating in a report on Friday, June 30th. Citigroup cut their price target on shares of Eiger BioPharmaceuticals from $4.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, August 29th.
Eiger BioPharmaceuticals Stock Performance
Institutional Trading of Eiger BioPharmaceuticals
Institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc boosted its holdings in Eiger BioPharmaceuticals by 62.0% during the second quarter. Legal & General Group Plc now owns 4,327 shares of the biotechnology company’s stock worth $27,000 after buying an additional 1,656 shares in the last quarter. BNP Paribas Arbitrage SA raised its holdings in Eiger BioPharmaceuticals by 208.7% during the second quarter. BNP Paribas Arbitrage SA now owns 9,307 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 6,292 shares during the last quarter. Credit Suisse AG acquired a new position in Eiger BioPharmaceuticals during the second quarter worth $66,000. BNP Paribas Arbitrage SNC raised its holdings in Eiger BioPharmaceuticals by 39.1% during the third quarter. BNP Paribas Arbitrage SNC now owns 12,948 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 3,641 shares during the last quarter. Finally, American International Group Inc. raised its holdings in Eiger BioPharmaceuticals by 20.7% during the second quarter. American International Group Inc. now owns 19,177 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 3,283 shares during the last quarter. Hedge funds and other institutional investors own 62.46% of the company’s stock.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.
- Five stocks we like better than Eiger BioPharmaceuticals
- How to Use the MarketBeat Stock Split Calculator
- MarketBeat Week in Review – 8/28 – 9/1
- Airline Stocks – Top Airline Stocks to Buy Now
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.